Authors
Latest:
Organizational Design and Talent Strategy in the Changing Biopharma LandscapeWithout considering the organizational and talent aspects of change, companies put themselves at risk for poor employee engagement, loss of talent, and ultimately, failed business initiatives, writes Viq Prevaaz.
Latest:
The New (Augmented) Reality in the Life SciencesThree ways AR can bolster pharma commercialization strategies.
Latest:
Post-Pandemic Physician Engagement: 4 Areas to Consider When Rethinking Your Sales Talent and Their ApproachCOVID-19 has been game-changing for pharma sales, driving demand for new models and reps with the right competencies and skills to succeed in a hybrid sales environment.
Latest:
Planning for Post-Deal IntegrationJo Pisani and Cynthia Chan outline the key legal considerations for post-deal integration.
Latest:
Moving Scientists from the Lab to the Executive SuiteThis op-ed discusses the varying skills that business leaders should look at in scientists when thinking about talent for the lab and the executive suite.
Latest:
Improving Persistence: Brand Team Dos and Don'tsIn Part 4 of a 4-part series on brand teams, this article discusses the tactics brand teams and partners should follow to improve medication and persistence.
Latest:
Next-Gen Patient Support Programs Gain Momentum in the Quest for ValueThere’s a growing realization that advances in connected devices, sensors and predictive analytics represent a game-changer when it comes to patient support programs (PSPs), writes Jim O'Donaghue.
Latest:
3 Behavioral Biases that Stunt the Potential of MarketersAs marketers mine for insights, they need to be keenly aware of the behavioral biases that can undermine their efforts, writes Kunsan Kim.
Latest:
Organizational Design and Talent Strategy in the Changing Biopharma LandscapeWithout considering the organizational and talent aspects of change, companies put themselves at risk for poor employee engagement, loss of talent, and ultimately, failed business initiatives, writes Viq Prevaaz.
Latest:
Atopic Dermatitis — Going Beyond the PillThere is a real opportunity for pharma to support the under-served population of atopic dermatitis patients, writes Mariel Metcalfe.
Latest:
Medical Affairs’ Search for MeaningThe need to look beyond the function’s traditional performance measures to the one that really matters-patient outcomes.
Latest:
Medical Affairs’ Search for MeaningThe need to look beyond the function’s traditional performance measures to the one that really matters-patient outcomes.
Latest:
Medical Affairs’ Search for MeaningThe need to look beyond the function’s traditional performance measures to the one that really matters-patient outcomes.
Latest:
ICH E2B (R3) EudraVigilanceImpact, challenges and the importance of ensuring readiness with ICH E2B (R3) EudraVigilance.
Latest:
Establishing End-to-End Control of Product Labelling: A Guide for the C-SuiteGraham Francis sets out 5 critical business drivers for building a global enterprise labelling strategy over the year ahead.
Latest:
How Copay Management by Payers Is EvolvingA look into the complex battle between pharmaceutical manufacturers and payers for balance between medication access and budget management.
Latest:
The AI Boom in Healthcare: How Manufacturers Can PrepareKellie Rademacher identifies some of the key questions to consider when choosing an AI partner.
Latest:
Deploying the Cloud in GxP EnvironmentsMeeting the stringent cloud compliance and regulatory requirements in pharma.
Latest:
Productivity Vs. Compliance: The Balancing Act of ECM in Life SciencesWhile digital transformation in life sciences starts with digitization for compliance, it should be seen as a key lever of competitive advantage and success, writes Jaleel Shujath.
Latest:
Patient KOLs: Their Guide to Entering Crowded MarketsHow “patient influencers” look beyond price to help the industry evaluate newly-launched brands.
Latest:
Patient Empowerment and the Future of Pharma AdvertisingWith digitalization enabling patient engagement with their own health experience more than ever before, two critical elements will steer pharma’s advertising path.
Latest:
Clinical Trials Don't Have to Cost Too Much or Take Too LongA discussion of the cost and time put into clinical trials.
Latest:
Clinical Trials Don't Have to Cost Too Much or Take Too LongA discussion of the cost and time put into clinical trials.
Latest:
Clinical Trials Don't Have to Cost Too Much or Take Too LongA discussion of the cost and time put into clinical trials.
Latest:
KOLs: An Endangered BuzzwordKOLs have traditionally exerted their influence through research and publication on drug safety and efficacy, but now share the stage with other important measures.
